Japan health ministry approves Novocure Optune Pax for unresectable locally advanced pancreatic cancer

• Japan’s MHLW cleared Novocure’s Optune Pax for unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.
• Decision relied on Phase 3 PANOVA-3 results showing a statistically significant median overall survival gain versus chemotherapy alone.
• Optune Pax won FDA authorization in February 2026; it secured a CE mark in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001277516) on October 01, 2026, and is solely responsible for the information contained therein.